BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26195067)

  • 1. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
    Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
    Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
    Wang J; Jensen M; Lin Y; Sui X; Chen E; Lindgren CG; Till B; Raubitschek A; Forman SJ; Qian X; James S; Greenberg P; Riddell S; Press OW
    Hum Gene Ther; 2007 Aug; 18(8):712-25. PubMed ID: 17685852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity].
    Hu YX; Yu K; Tan YX; Shen ZJ; Jiang SF; Qian HL; Hang B; Shan DM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):111-4. PubMed ID: 17650672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
    Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
    Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
    Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
    J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
    Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
    J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
    Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
    Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
    Jensen MC; Popplewell L; Cooper LJ; DiGiusto D; Kalos M; Ostberg JR; Forman SJ
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1245-56. PubMed ID: 20304086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
    Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
    Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
    Panjwani MK; Smith JB; Schutsky K; Gnanandarajah J; O'Connor CM; Powell DJ; Mason NJ
    Mol Ther; 2016 Sep; 24(9):1602-14. PubMed ID: 27401141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
    Budde LE; Berger C; Lin Y; Wang J; Lin X; Frayo SE; Brouns SA; Spencer DM; Till BG; Jensen MC; Riddell SR; Press OW
    PLoS One; 2013; 8(12):e82742. PubMed ID: 24358223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.